Quick and Simple Technology Enhances the Potential of Stem Cells To Differentiate Into Adult Cells – Technology Networks

Mouse embryoid body with multiple cell types (in different colours) generated in vitro after expression of miR-203 in stem cells. Credit: CNIO

Read Time:

Stem cells have been holding great promise for regenerative medicine for years. In the last decade, several studies have shown that this type of cell, which in Spanish is called mother cell because of its ability to give rise to a variety of different cell types, can be applied in regenerative medicine for diseases such as muscular and nervous system disorders, among others. Researchers and stem cell pioneers Sir John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for this idea. However, one of the main limitations in the application of these cell therapies is the quality of the stem cells that can be generated in the laboratory, which impedes their use for therapeutic purposes. Now, a team from the Cell Division and Cancer Group of the Spanish National Cancer Research Centre (CNIO), led by researcher Marcos Malumbres, has developed a new, simple and fast technology that enhances in vitro and in vivo the potential of stem cells to differentiate into adult cells. The research results are published in The EMBO Journal.

In recent years, several protocols have been proposed to obtain reprogrammed stem cells in the laboratory from adult cells, but very few to improve the cells we already have. The method we developed is able to significantly increase the quality of stem cells obtained by any other protocol, thus favouring the efficiency of the production of specialised cell types, says Mara Salazar-Roa, researcher at the CNIO, first author of the article and co-corresponding author.

In this study, the researchers identified an RNA sequence, called microRNA 203, which is found in the earliest embryonic stages before the embryo implants in the womb and when stem cells still have their maximum capacity to generate all the different tissues. When they added this molecule to stem cells in the laboratory, they discovered that the cells ability to convert to other cell types improved significantly.

To corroborate this, they used stem cells of human and murine origin, and of genetically modified mice. The results were spectacular, both in mouse cells and in human cells. Application of this microRNA for just 5 days boosts the potential of stem cells in all scenarios we tested and improves their ability to become other specialised cells, even months after having been in contact with the microRNA, says Salazar-Roa.

According to the study, cells modified by this new protocol are more efficient in generating functional cardiac cells, opening the door to an improved generation of different cell types necessary for the treatment of degenerative diseases.

Malumbres, head of the CNIO Cell and Cancer Division Group, says: To bring this asset to the clinic, collaboration with laboratories or companies that want to exploit this technology is now necessary in each specific case. In this context, Salazar-Roa recently participated, in close collaboration with the CNIOs Innovation team, in prestigious innovation programs such as IDEA2 Global of the Massachusetts Institute of Technology (MIT) and CaixaImpulse of the la Caixa Foundation, from which they also obtained funding to start the development of this technology.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to read the rest:
Quick and Simple Technology Enhances the Potential of Stem Cells To Differentiate Into Adult Cells - Technology Networks

California voters: Here are the 12 measures on the November ballot – San Francisco Chronicle

Californians will see a lengthy list of initiatives and referendums on the November ballot.

Secretary of State Alex Padilla has assigned proposition numbers to 12 measures that have qualified for the ballot, from funding for stem cell research to a repeal of the states ban on affirmative action and an expansion of consumer privacy laws. Each must be approved by a simple majority to become law.

Proposition 14: Stem cell research. Would re-fund the California Institute for Regenerative Medicine, the states stem cell agency, by allowing it to issue $5.5 billion in bonds for research, training and facilities construction.

Proposition 15: Limits on property taxes. Would rewrite Proposition 13, the landmark 1978 measure that limits property tax increases and allows residential and commercial property to be reassessed only when it is sold.

Prop. 15 would boost property taxes on large commercial and industrial property by allowing it to be reappraised more frequently. The added money would go to school districts and local governments. Prop. 13 rules for residential property would be unchanged.

Proposition 16: Affirmative action. A constitutional amendment, proposed by state legislators, that would reverse Californias voter-approved 1996 ban on affirmative action. It would repeal Proposition 209, which prohibits public universities, schools and government agencies from using race or sex in their admissions criteria, hiring and contract decisions.

Proposition 17: Parolee voting. A constitutional amendment, proposed by state legislators, that would restore the voting rights of all people on parole if theyve completed their state or federal prison terms.

Proposition 18: Voting age. A constitutional amendment, proposed by state legislators, that would allow 17-year-olds to vote in primary elections if they would turn 18 before the general election.

Proposition 19: Property tax transfers. A constitutional amendment, proposed by state legislators, that would allow people age 55 and older, and victims of wildfires and other disasters, to keep lower property tax rates when they move to new homes.

Proposition 20: Criminal justice. Would make changes to the criminal justice system by revising two earlier initiatives, Proposition 47 and Proposition 57. The new measure would expand the list of violent crimes for which there is no early release, adding sex trafficking of a child and felony domestic violence. It would also require DNA collection for those convicted of several types of misdemeanors.

Proposition 21: Rent control. Would reverse a ban on local rent control laws. It would repeal the Costa-Hawkins Rental Housing Act, which prohibits cities from passing rent control ordinances for housing built since 1995. Voters overwhelmingly rejected a similar measure in 2018.

An earlier version of this story erroneously stated that two additional measures could qualify for the November ballot. The window for qualifying has closed.

Proposition 22: Gig worker classification. Would exempt app-based drivers, including those working for Uber, Lyft and DoorDash, from a state law that classifies gig workers as employees. The companies want to undo part of AB5, Californias gig-worker law, which aims to classify their drivers as employees and make them eligible for benefits. Under the ballot measure, the companies could keep drivers as independent contractors while granting them some benefits and earnings guarantees.

Proposition 23: Kidney dialysis clinics. Would increase state regulation of kidney dialysis clinics. Among the proposed requirements: Clinics would be prohibited from discriminating against patients based on their source of payment.

Proposition 24: Consumer data privacy. Would expand Californias consumer privacy law, passed in 2018. The measure would triple penalties for companies that break laws regarding the collection and sale of childrens private information. It would also create a state agency to enforce consumer privacy protections.

Proposition 25: Cash bail. Would overturn a 2018 law that eliminates cash bail as a requirement to release people from jail before trial.

Dustin Gardiner is a San Francisco Chronicle staff writer. Email: dustin.gardiner@sfchronicle.com Twitter: @dustingardiner

Dustin Gardiner is a state Capitol reporter for The San Francisco Chronicle. He joined The Chronicle in 2019, after nearly a decade with The Arizona Republic, where he covered state and city politics. Dustin won several awards for his reporting in Arizona, including the 2019 John Kolbe Politics Reporting award, and the 2017 Story of the Year award from the Arizona Newspapers Association. Outside of work, he enjoys hiking, camping, reading fiction and playing Settlers of Catan. He's a member of NLGJA, the association of LGBTQ journalists.

Outdoors

July 4th

COVID-19

Tenderloin

Giants

Original post:
California voters: Here are the 12 measures on the November ballot - San Francisco Chronicle

Stem Cell Banking Market Global Industry Analysis and Opportunity and Forecast 2018 to 2028 – Cole of Duty

Global Stem Cell Banking Market: Overview

The demand within the global stem cell banking market is growing on account of advancements in the field of regenerative medicine. The medical fraternity has become extremely focused towards the development of artificial tissues that can infuse with the human body. Furthermore, medical analysis and testing has gathered momentum across biological laboratories and research institutes. Henceforth, it is integral to develop stem cell samples and repositories that hold relevance in modern-day research. The need for regenerative medicine emerges from the growing incidence of internal tissue rupture. Certain types of tissues do not recover for several years, and may even be damaged permanently. Therefore, the need for stem cell banking is expected to grow at a significant pace.

Download Brochure of This Market Report at https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6111

In a custom report, TMR Research digs into the factors that have aided the growth of the global stem cell banking market. The global stem cell banking market can be segmented on the basis of bank size, application, and region. The commendable developments that have incepted across the US healthcare industry has given a thrust to the growth of the North America stem cell banking market.

Global Stem Cell Banking Market: Notable Developments

The need for improved regenerative medication and anatomy has played an integral role in driving fresh developments within the stem cell banking market.

Gallant has emerged as a notable market entity that has remained as the torchbearer of innovation within the global stem cell banking market. The company has recently launched stem cell banking for dogs, and has attracted the attention of the masses. As people become increasingly concerned about their pets, the new move by Gallant shall help the company in earning the trust of the consumers. Moreover, it can move several notches higher on the innovation index.

Cells4Life has also remained at the forefront of developments within the global stem cell banking market. After suffering backlash for its error in cord blood stem cell promotion, the company is expected to use effective public relation strategies to regain its value in the market.

Global Stem Cell Banking Market: Growth Drivers

Development of improved facilities for storage of stem cells has played an integral role in driving market demand. Furthermore, the unprecedented demand for improved analysis of regenerative medications has also created new opportunities within the global stem cell banking market. Medical research has attracted investments from global investors and stakeholders. The tremendous level of resilience shown by biological researchers to develop stem cell samples has aided market growth. Henceforth, the total volume of revenues within the global stem cell banking market is slated to multiply.

Commercialization of stem cell banks has emerged as matter of concern for the healthcare industry. However, this trend has also helped in easy storage and procurement of cells stored during the yester years of children. Presence of sound procedures to register at stem cell banks, and the safety offered by these entities, has generated fresh demand within the global market. New regional territories are opening to the idea of stem cell banking. Several factors are responsible for the growth of this trend. Primarily, improvements in stem cell banking can have favourable impact on the growth of the healthcare industry. Moreover, the opportunities for revenue generation associated with the development of functional stem cell banks has aided regional market growth.

The global stem cell banking market is segmented on the basis of:

Source

Request For TOC On this Market Report at https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6111

See more here:
Stem Cell Banking Market Global Industry Analysis and Opportunity and Forecast 2018 to 2028 - Cole of Duty

Props To You, Californians: A Preview Of What’s On Your November Ballot – KPBS

After a bit of last-minute legislative maneuvering, the list of propositions that California voters will be asked to weigh in on has been more or less finalized.

This past week marked the deadline for citizens and special interests to snag their spot on the November ballot. Eight measures made the cut. They address matters as vital and/or esoteric as rent control, property tax law, dialysis clinic staffing requirements, stem cell research funding and the preservation or final dispatch of cash bail in California.

The same date also marked the deadline for legislators to place their preferred measures on the November ballot. But lawmakers have a bit more flexibility when it comes to deadlines they can just make new laws. On Monday, the Senate passed Senate Bill 300 to Gov. Gavin Newsom who signed it. The law effectively extended the Legislatures deadline to July 1.

(Technically, the deadline wasnt extended but created anew. The law calls for the Legislatures favored measures to go before voters in a whole new election conveniently to take place on the same day and same ballot as the ordinary November 3 election.)

That extension gave lawmakers a few extra hours to add four measures: two to expand voting rights, one that ends a 22-year-old ban on affirmative action, and one that is a tortuously complicated property tax measure that somehow ropes in Realtors, wildland firefighters and The Dude from the Big Lebowski.

Heres your November ballot preview:

These three measures, all placed on the ballot by the Legislature, had been introduced before protests against racism and police brutality swept the country. But as California lawmakers look for ways to play a role in the national debate about institutional barriers to equity and the meaning of citizenship, many legislators see these as particularly potent causes.

Prop. 16: Ending the ban on affirmative action

Who put it there: The Legislature, via a bill by San Diego Democrat Assemblymember Shirley Weber

Type: Constitutional amendment

What it would do: Allow schools and public agencies to take race and other immutable characteristics into account when making admission, hiring or contracting decisions.

In 1996 California voters passed Proposition 209, a constitutional amendment banning affirmative action at state institutions. The result was an immediate drop in Black and Latino enrollment at the states elite public universities. Some civil rights organizations have been trying to repeal Prop. 209 ever since.

Each of those attempts has been stymied by a coalition of Republicans, moderate Democrats and some progressive legislators who represent districts with large Asian American voting populations. This year, as in previous years, some of the most vocal and persistent opponents of the effort to reintroduce affirmative action have been Chinese-American political activists. They argue that boosting enrollment of students from underrepresented racial groups would come at the expense of overrepresented Asian American students.

Prop. 17: Restoring the right to vote to people on parole

Who put it there: The Legislature, via a bill by Sacramento Democrat Assemblymember Kevin McCarty.

Type: Constitutional amendment

What it would do: Allow Californians who are currently on parole to vote.

In 1974, California voters passed a ballot measure giving people who have committed felonies the right to vote once they complete their sentences and are no longer on parole.

Thanks to that law, there are some 40,000 Californians who are not in prison but unable to legally cast a ballot. But as with any criminal justice debate, this is also one about race. According to an estimate from 2016, two thirds of people on parole in the state are Latino or Black.

Prop. 18: Letting (some) 17 year olds vote (some of the time)

Who put it there: The Legislature, with a bill introduced by San Mateo Democrat Assemblymember Kevin Mullin.

Type: Constitutional amendment

What it would do: Allow 17-year-old U.S. citizens to vote in a primary and special election as long as they will turn 18 by the subsequent general election.

California Democrats have been on a decade-long tear increasing voting access. Same-day voter registration, automatic registration at the DMV and pre-registration of 16- and 17-year-olds are among the recent pro-vote innovations to come out of the Capitol.

Letting people under 18 vote would be yet another extension. Already 23 states let 17- year-olds vote in certain circumstances.

Democratic legislators have tried to do this six times before; this is the first to make the ballot.

This wouldnt be a California election without at least a few wildy contentious ballot measures about housing and property taxes.

Prop. 15: Split roll

Who put it there: Citizens. Campaign largely funded by the California Teachers Association, SEIU California and the Chan Zuckerberg Initiative.

Type: Constitutional amendment

What it would do: Tax some commercial property based on its market value, rather than the price at which it was purchased. This would raise property taxes on many large businesses across the state, increasing funding for schools and local government.

In 1978, California voters passed Proposition 13, placing a cap on property taxes, kicking off a nationwide anti-tax revolt and placing city and county budgets in a generation-spanning straitjacket.

By tying a landlords property tax payments to the original purchase price, Prop. 13 has been the gift that keeps on giving to property owners, particularly those lucky enough to have bought cheap real estate decades ago. Theres been bipartisan reluctance among lawmakers to touch it ever since, lest they incur the wrath of irate homeowners.

This initiative attempts to divide and conquer that political problem by repealing the property tax protections only for commercial landlords with more than $3 million in holdings. If this measure passes, those landowners would have to make tax payments based on the current value of their properties a tax hike for most resulting in an estimated $6.5 to $11.5 billion more for cities, counties and school districts.

Prop. 19: Property tax breaks and closing the Lebowski loophole

Who put it there: The Legislature, via a bill by San Mateo Democrat Assemblymember Kevin Mullin, but sponsored by the California Realtors.

Type: Constitutional amendment

What it would do: Allow homeowners who are over 55, disabled or victims of natural disaster to take a portion of their property tax base with them when they sell their home and buy a new one. It would also limit the ability of new homeowners who inherit properties to keep their parents or grandparents low property tax payments. Most of the additional money raised would go into a state fire response fund.

Weve seen this one before half of it, anyway. In 2018, the California Association of Realtors put a measure on the ballot allowing older or disabled homeowners to keep a portion of their Prop. 13 tax break. The Realtors argued that the current property tax rules disincentivize longtime homeowners from moving, trapping empty-nesters in houses that are too big for them and locking out new families. But because the measure would cost schools, counties and cities, it was opposed by organized labor and local government groups and failed by 20 points.

The Realtors tried again this year, but with an added fiscal sweetener. Under this proposal, anyone who inherits a home from their parents or grandparents would only be allowed to keep the low property taxes if they use the home as their primary residence and only on the first $1 million between the homes original purchase price and its market value. Inspiration for that caveat may have come from the Los Angeles Times, which tracked down a number of California scions, including The Big Lebowski star Jeff Bridges, who are still paying 1970-era property tax levels on their rental properties.

And then there was a last-minute wrinkle. In the final weeks of June, the Realtors sprang a deal: designating that most of the funding generated by the measure would go to fighting wildfires. That won the support of the influential California Professional Firefighters union. It also means the measure will be funding a public need that might be on many voters minds come November.

That bargain was struck after the Realtors had submitted their signatures, so with the help of Assemblyman Mullin, they passed it through the Legislature, pulling their original proposal just before the deadline.

Who put it on the ballot: Signatures, collected via an effort mostly funded by the AIDS Healthcare Foundation.

Type: Statute

What it would do: Allow cities to introduce new rent control laws, or expand existing ones.

Despite a 20-percentage point, 56-out-of-58 county defeat in 2018, a statewide rent control measure is back on the ballot.

Polling from that election season suggested that California voters generally liked rent control as a concept, but worried about the specifics of the proposal. Accordingly, this new initiative makes a few tweaks.

Under this one, cities would be allowed to apply new rent control ordinances only to homes that are at least 15 years old. And it exempts single-family homes owned by landlords with no more than two properties.

Just like last time, the measure is being pushed by the Los Angeles-based AIDS Healthcare Foundation and its pugnacious president Michael Weinstein. State lawmakers by passing a law last year that set a 7% ceiling on how much landlords can raise rents each year had hoped to ward off another attempt by Weinstein and company. They had no such luck.

California, the home of three-strikes sentencing, has spent the last decade rethinking its approach to criminal justice. Two measures on the November ballot, channeling the spirit of the 90s, are pushing to reverse that reversal.

Prop. 25: Ditch or keep cash bail

Who put it there: Signatures, via a campaign largely funded by the bail bond industry.

Type: Referendum

What it would do: Ask voters to either approve or strike down a state law that banished money bail from the state criminal justice system.

In 2018, acting on the advice of state Supreme Court Chief Justice Tani Cantil-Sakauye, legislators passed a bill ending cash bail in California. Rather than letting people pay their way out of jail while they await trial, the law gives judges the right to determine whether someone who is arrested should be kept behind bars based on the risk they are deemed to pose to themselves or others.

Moving quickly, the bail bond industry mounted a campaign to put the question on the ballot as a referendum. Voters will vote either Yes to keep the state law and end cash bail for good, making California the first state to do so, or No to keep the bail system.

Prop. 20: Rolling back Brown-era leniency

Who put it there: Signatures, via a campaign largely funded by law enforcement agencies.

Type: Constitutional amendment

What it would do: Allow prosecutors to charge repeat or organized petty theft as a felony, require probation officers to seek tougher penalties for those who violate the term of their parole three times, and exclude those who have been convicted of domestic violence and certain nonviolent crimes from early parole consideration.

Gov. Jerry Brown was famously allergic to talk of his legacy while in office. But if the former governor has one, it might be the effort he spent in his final two terms as governor supporting efforts to reverse the tough on crime policies he helped introduce during his first two terms in the 1970s and 80s.

In 2011, California legislators reduced punishments for parole violators. In 2014, voters passed Proposition 47, recategorizing some non-violent crimes as misdemeanors. In 2016, voters passed Proposition 57, giving inmates convicted of certain non-violent offenses a shot at early release.

This ballot measure would partially undo each of those.

Usually standoffs between employees and their bosses take place behind closed doors. In California, you often find them on the ballot.

Prop. 22: Self-employment for ride-hail and other app-drivers

Who put it there: Signatures, via a campaign mostly funded by Lyft, Uber and Doordash

Type: Statute

What it would do: Turn app-based drivers into independent contractors, exempting companies such as Lyft and Uber from standard wage and hour restrictions. It would also guarantee these drivers an earnings floor, a stipend to purchase health insurance and other minimum benefits.

Unless you happen to be an anti-vaccine protestor, the most controversial law of the 2019 legislative session was Assembly Bill 5. On its face, the law simply codified a state Supreme Court ruling, making it much harder for companies to treat their workers as independent contractors, rather than full-fledged employees. In practice, it upended the business models of Uber, Lyft, Doordash, Postmates and Instacart, all of which rely on an army of phone-toting gig-workers to provide their various services.

In the months since, all attempts at legislative compromise have fizzled, Californias Attorney General has sued Uber and Lyft for violating the new law and California regulators declared their drivers to be employees.

As a last-ditch effort, the various companies implicated have poured $110 million and counting to push a ballot measure that would simply exclude their drivers from the law. And throwing a bone to critics who say their drivers are mistreated, the measure also imposes some worker benefits and protections.

Prop. 23: Regulating dialysis clinics

Who put it there: Signatures, via an effort funded entirely by the Service Employees International Union-United Healthcare Workers West

Type: Statute

What it would do: Require dialysis clinics to have at least one physician on site at all times and to report patient infection data to California health officials.

DaVita Kidney Care and Fresenius Medical Care own the majority of the for-profit dialysis clinics in the state. For years, the Service Employees International Union-United Healthcare Workers union has been at war with them.

After unsuccessful efforts to unionize clinic staff, the union sponsored legislation to cap reimbursement rates to clinics and floated an array of possible ballot measures to boost their staff spending and cut their profits. In 2018, the union finally got one on the ballot: Prop 8, which would have set a cap on clinic profit margins.

The measure was soundly defeated, but only after the two companies spent over $111 million, making it the most expensive ballot campaign ever. This one isnt likely to be much cheaper.

Two measures on this years ballot aim to bolster laws and programs already on the books. Both campaigns are led by Bay Area real estate developers with a penchant for ballot box policymaking.

Prop. 24: Stronger consumer privacy laws (again)

Who put it there: Signatures, via a campaign funded entirely by Alastair and Celine Mactaggart.

Type: Statute

What it would do: Strengthen Californias already strongest-in-the-nation consumer privacy law and establish a California Privacy Protection Agency

In 2018, California lawmakers passed the California Consumer Privacy Act, giving consumers the right to find out what data companies are collecting about them, to opt out of having it collected and to have that data scrubbed. It was and remains the only law like it in the county. It was also a compromise. San Francisco real estate developer Alastair MacTaggart had been pushing for an even stricter ballot measure, but the Legislature stepped in, brokering a deal between MacTaggart and the tech industry.

Now MacTaggart is back. Along with setting up a state agency tasked with enforcing state privacy law, the measure would beef up financial penalties for violators and allow consumers to demand that personal information not be shared at all, rather than simply not sold.

Who put it there: Signatures via an effort mostly funded by Robert Klein, JDRF International and Open Philanthropy

Type: Bond

What it would do: Borrow $5.5 billion to fund stem cell research

In 2004, voters passed Proposition 71 to create the California Institute for Regenerative Medicine. The institute exists to channel state money toward stem cell research. Prop 71 also let the state borrow $3 billion to do that.

That pot of cash is now almost empty. Robert Klein, a Silicon Valley real estate developer who led the Prop. 71 effort and became the institutes first board chair, is leading the campaign for more.

Correction: This story has been corrected to reflect that Robert Klein was the first board chair of the California Institute for Regenerative Medicine.

The California Dream Project is a statewide collaboration focused on issues of economic opportunity, quality-of-life, and the future of the California Dream. Partner organizations include CALmatters, Capital Public Radio, KPBS, KPCC, and KQED.

KPBS' daily news podcast covering local politics, education, health, environment, the border and more. New episodes are ready weekday mornings so you can listen on your morning commute.

To view PDF documents, Download Acrobat Reader.

More here:
Props To You, Californians: A Preview Of What's On Your November Ballot - KPBS

Korea to invest 2.8 trillion in promoting bio-health sector – Korea Biomedical Review

The government unveiled its plans to invest 2.8 trillion won ($2.3 billion) in developing new key technologies to foster the bio-health industry over the next decade.

The Ministries of Health and Welfare, Science and ICT, and Trade, Industry and Energy said on Friday that two interagency projects -- new drug development and regenerative medicine technology development -- had passed the preliminary feasibility study last month.

The two national projects are part of the Bio-Health Industry Innovation Strategy announced by the government in May last year.

In pursuing new drug development as a state project, the government will provide step-by-step support, starting from basic research, going through nonclinical and clinical trials, and reaching test manufacture and mass production.

According to the viability study, the project will likely create 2.1 trillion won in industrial production for 10 years from 2021, to emerge as the largest R&D project to be conducted by the Ministry of Health and Welfare.

The three ministries said they plan to support the project by abolishing barriers as if they were one ministry. To this end, they have established a unified administrative system for the project by building up their capabilities, providing integrated consultation and support customized to the needs of universities, research institutions, and businesses.

Through the project, the government aims to develop blockbuster new drugs, each with annual sales of more than 1 trillion won ($830 million) over the next decade while enhancing the pharmaceutical industry's competitiveness.

Concerning the development of regenerative medicine technology, the government will provide support throughout the period, from the core basics and the original technology to the clinical stage of therapeutic and therapeutic technologies for regenerative medicines.

The field of regenerative medicine, despite expectations as a future medical technology, has experienced limitations in developing new technologies because of the legal system.

After the National Assembly passed the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals last year, research and development conditions and ecosystems for the regenerative medicine field have made marked improvement.

Encouraged by the brighter prospect, the government has decided to invest 595.5 billion won in this area for 10 years from 2021.

It plans to focus on strengthening the technological competitiveness of stem cell therapy products and core technologies with high potential for future growth, such as gene therapy and tissue engineering materials.

"Through the development of the bio-health industry, we will develop innovative new drugs to treat rare, incurable diseases, protect health sovereignty through localization of pharmaceuticals and medical technologies, and strengthen public health," said Im In-taek, director-general of the Health Industry Policy Bureau in the health and welfare affairs ministry.

Based on the results of the recent preliminary feasibility study, the three related ministries will go all out for the project's success, Im added.

corea022@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

View post:
Korea to invest 2.8 trillion in promoting bio-health sector - Korea Biomedical Review

Global Stem Cell Assay Market with COVID-19 After Effects Analysis by Key Players | GE Healthcare, Promega Corporation, Thermo Fisher Scientific,…

Stem Cell Assay Industry Overview Competitive Analysis, Regional and Global Analysis, Segment Analysis, Market Forecasts 2026

The new report on the globalStem Cell Assay marketpublished by theMarket Research Storeincorporates all the essential facts about the Stem Cell Assay market. This aids different industry players along with new market entrants to open new gateways for the Stem Cell Assay market on a global platform. Through in-depth research and data obtained from the reliable database the qualitative and the quantitative data of the Stem Cell Assay market has been updated based on the current market conditions owing toCOVID-19. The overall market conditions have been affected due to the pandemic. The trading conditions and the economy crisis have affected the Stem Cell Assay market. The information in the Stem Cell Assay market report is updated and precise thus the clients will be able to relate themselves to the current market scenario.

Request Free Sample Copy of Stem Cell Assay Market Research Report@http://www.marketresearchstore.com/report/global-stem-cell-assay-market-report-2019-industry-442702#RequestSample

The Stem Cell Assay market report also encompasses the details about all the market players that are operating in the Stem Cell Assay market. The market players includeGE Healthcare, Promega Corporation, Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Bio-Techne Corporation, Cellular Dynamics International, Cell Biolabs, Hemogenix, Stemcell Technologies.

The market analysis in the Stem Cell Assay market study starts with the market definition and scope. In the next section, there is a brief discussion about the target audience of the market. In the later section, a detailed information about the market growth factors and limitations are discussed along with the market opportunities and challenges that are being faced owing to arise of the pandemic. Research tools and methodologies were used while analyzing the Stem Cell Assay market.

Read Detailed Index of full Research Study at::http://www.marketresearchstore.com/report/global-stem-cell-assay-market-report-2019-industry-442702

The major section that covers the overall market description is the market segmentation. The Stem Cell Assay market includes segments{Dermatology Stem Cell Assay, Cardiovascular Stem Cell Assay, Central Nervous System Stem Cell Assay, Oncology Stem Cell Assay, Other}; {Regenerative Medicine & Therapy Development, Drug Discovery and Development, Clinical Research, Other}. To study any market in detail the major components that need to be analyzed are its product type, application, end-use, the solution and the services that are offered. Details about all these segments helps better understand the market size and demand. Every aspect of every single segment was studied carefully and the impact of COVID-19 was also taken into consideration. Both numerical data and subjective information about every segment is included for better understanding. The regional presence of the Stem Cell Assay market is also included. The current market condition in each regions is explained thoroughly as to how the pandemic has affected the Stem Cell Assay market demand in a particular region.

Major Advantages for Stem Cell Assay Market:

1. Well-organized description of the international Stem Cell Assay market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas. 2. The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the Stem Cell Assay industry. 3. The Stem Cell Assay market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis. 4. The current market is quantitatively reviewed from 2019 to 2028 to pinpoint the monetary competency of the global Stem Cell Assay market. 5. Last but not least, PORTERS Five Forces Analysis shows the effectiveness of the customers and providers from a global perspective.

If Any Inquiry of Stem Cell Assay Report:http://www.marketresearchstore.com/report/global-stem-cell-assay-market-report-2019-industry-442702#InquiryForBuying

Go here to see the original:
Global Stem Cell Assay Market with COVID-19 After Effects Analysis by Key Players | GE Healthcare, Promega Corporation, Thermo Fisher Scientific,...

28 cool health things that started with a Canadian – Regina Leader-Post

Alzheimers in mice

Dr. Peter St George-Hyslopof the Weston Brain Institute identified a number of genes responsible for Alzheimers disease and nerve cell degeneration using mouse models. He has published nearly 400 papers on Alzheimers research.

In the early 2000s, he essentially cured Alzheimers in mice through the discovery that certain types of sugars would block the development of amyloid proteins, one of the hallmarks of Alzheimers.

Genomics

University of Torontos Brenda Andrews pioneered the field of functional genomics and systems biology to discover how genes and their protein products regulate cell function in health and disease. She is also an elected member of the National Academy of Sciences and a specialist in the application of artificial intelligence to personalized medicine.

Kathleen Dickson is a former chief technician from the Montreal Neurological Institute.

John Bergeron is the Emeritus Robert Reford Professor and a Professor of Medicine at McGill University.

Dont miss the latest on COVID-19, reopening and life. Subscribe to Healthings daily newsletterComing Out of COVID.

Read more:
28 cool health things that started with a Canadian - Regina Leader-Post

Lungs in Vitro Market 2020 Opportunities, Growth Analysis, Trends and Forecast by 2024 | ATCC, Lonza, Epithelix – 3rd Watch News

Competitive Market Research Report on Global Lungs in Vitro Market with focus on Industry Analysis, Growth Opportunities, Risk Analysis, Current Trends, Competitive Landscape, Investment Strategies and Forecast by 2024.

The report contains in-depth information on all the key aspects of the global Lungs in Vitro market. This report contains important data such as facts & figures, market research, market analysis, SWOT analysis, competitive landscape, regional analysis and future growth prospects. The report also contains qualitative and quantitative research which gives you a detailed analysis of the global Lungs in Vitro market. The report is perfect as you can see information on the recent developments, based on which you can make risk assessments and investments in the Lungs in Vitro industry.

Get The Sample Report PDF with Detail TOC & List of [emailprotected]https://marketresearchport.com/request-sample/5147

Leading Companies Covered:

ATCC, Lonza, Epithelix, Mattek, Emulate, Mimetas, Tissuse, Insphero, Cn Bio

This global Lungs in Vitro market research report has data of all the leading players operating in the industry. From their market shares in the industry, to their growth plans, recent development status, all important information has been compiled in the report to let you get an insightful look at the top players operating in the industry. The report includes the forecasts, analysis and discussion of important industry trends, market size, market share estimates and profiles of the leading industry players.

Market Research is Further Divided into Following Segments:

Market Segmentation by Product Types: 2D Cell Models, 3D Cell Models, Commercial 3D Cell Models, Inhouse 3D Cell Models

Market Segmentation by Applications: Drug Screening, Toxicology, 3D Model Development, Basic Research, Physiologic Research, Stem Cell Research, Regenerative Medicine

Regions Mentioned in the Global Lungs in Vitro Market:

The Middle East and Africa North America South America Europe Asia-Pacific Middle East Oceania Rest of the World

The data of the market research report has been studied, compiled and corroborated by leading industry experts and established authors. The format followed in the report is in accordance with most international market research reports. However, if you have any specific requirements, just get in touch with us, and we will customize the report accordingly as per your needs.

Do Enquiry For Customized Report as per Your [emailprotected]https://marketresearchport.com/enquiry-before-buying/5147

Table of Content: 1 Industry Overview of Lungs in Vitro 1.1 Brief Introduction of Lungs in Vitro 1.1.1 Definition of Lungs in Vitro 1.1.2 Development of Lungs in Vitro Industry 1.2 Classification of Lungs in Vitro 1.3 Status of Lungs in Vitro Industry 1.3.1 Industry Overview of Lungs in Vitro 1.3.2 Global Major Regions Status of Lungs in Vitro

2 Industry Chain Analysis of Lungs in Vitro 2.1 Supply Chain Relationship Analysis of Lungs in Vitro 2.2 Upstream Major Raw Materials and Price Analysis of Lungs in Vitro 2.3 Downstream Applications of Lungs in Vitro

3 Manufacturing Technology of Lungs in Vitro 3.1 Development of Lungs in Vitro Manufacturing Technology 3.2 Manufacturing Process Analysis of Lungs in Vitro 3.3 Trends of Lungs in Vitro Manufacturing Technology

4 Major Manufacturers Analysis of Lungs in Vitro 4.1 Company 1 4.1.1 Company Profile 4.1.2 Product Picture and Specifications 4.1.3 Capacity, Production, Price, Cost, Gross and Revenue 4.1.4 Contact Information 4.2 Company 2 4.2.1 Company Profile 4.2.2 Product Picture and Specifications 4.2.3 Capacity, Production, Price, Cost, Gross and Revenue 4.2.4 Contact Information 4.3 Company 3 4.3.1 Company Profile 4.3.2 Product Picture and Specifications 4.3.3 Capacity, Production, Price, Cost, Gross and Revenue 4.3.4 Contact Information 4.4 Company 4 4.4.1 Company Profile 4.4.2 Product Picture and Specifications 4.4.3 Capacity, Production, Price, Cost, Gross and Revenue 4.4.4 Contact Information 4.5 Company 5 4.5.1 Company Profile 4.5.2 Product Picture and Specifications 4.5.3 Capacity, Production, Price, Cost, Gross and Revenue 4.5.4 Contact Information 4.6 Company 6 4.6.1 Company Profile 4.6.2 Product Picture and Specifications 4.6.3 Capacity, Production, Price, Cost, Gross and Revenue 4.6.4 Contact Information 4.7 Company 7 4.7.1 Company Profile 4.7.2 Product Picture and Specifications 4.7.3 Capacity, Production, Price, Cost, Gross and Revenue 4.7.4 Contact Information 4.8 Company 8 4.8.1 Company Profile 4.8.2 Product Picture and Specifications 4.8.3 Capacity, Production, Price, Cost, Gross and Revenue 4.8.4 Contact Information 4.9 Company 9 4.9.1 Company Profile 4.9.2 Product Picture and Specifications 4.9.3 Capacity, Production, Price, Cost, Gross and Revenue 4.9.4 Contact Information 4.10 Company ten 4.10.1 Company Profile 4.10.2 Product Picture and Specifications 4.10.3 Capacity, Production, Price, Cost, Gross and Revenue 4.10.4 Contact Information

5 Global Productions, Revenue and Price Analysis of Lungs in Vitro by Regions, Manufacturers, Types and Applications 5.1 Global Production, Revenue of Lungs in Vitro by Regions 2014-2019 5.2 Global Production, Revenue of Lungs in Vitro by Manufacturers 2014-2019 5.3 Global Production, Revenue of Lungs in Vitro by Types 2014-2019 5.4 Global Production, Revenue of Lungs in Vitro by Applications 2014-2019 5.5 Price Analysis of Global Lungs in Vitro by Regions, Manufacturers, Types and Applications in 2014-2019

6 Global and Major Regions Capacity, Production, Revenue and Growth Rate of Lungs in Vitro 2014-2019 6.1 Global Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.2 Asia Pacific Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.3 Europe Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.4 Middle East & Africa Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.5 North America Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019 6.6 Latin America Capacity, Production, Price, Cost, Revenue, of Lungs in Vitro 2014-2019

7 Consumption Volumes, Consumption Value, Import, Export and Sale Price Analysis of Lungs in Vitro by Regions 7.1 Global Consumption Volume and Consumption Value of Lungs in Vitro by Regions 2014-2019 7.2 Global Consumption Volume, Consumption Value and Growth Rate of Lungs in Vitro 2014-2019 7.3 Asia Pacific Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.4 Europe Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.5 Middle East & Africa Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.6 North America Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.7 Latin America Consumption Volume, Consumption Value, Import, Export and Growth Rate of Lungs in Vitro 2014-2019 7.8 Sale Price Analysis of Global Lungs in Vitro by Regions 2014-2019

8 Gross and Gross Margin Analysis of Lungs in Vitro 8.1 Global Gross and Gross Margin of Lungs in Vitro by Regions 2014-2019 8.2 Global Gross and Gross Margin of Lungs in Vitro by Manufacturers 2014-2019 8.3 Global Gross and Gross Margin of Lungs in Vitro by Types 2014-2019 8.4 Global Gross and Gross Margin of Lungs in Vitro by Applications 2014-2019

9 Marketing Traders or Distributor Analysis of Lungs in Vitro 9.1 Marketing Channels Status of Lungs in Vitro 9.2 Marketing Channels Characteristic of Lungs in Vitro 9.3 Marketing Channels Development Trend of Lungs in Vitro

10 Global and Chinese Economic Impacts on Lungs in Vitro Industry 10.1 Global and Chinese Macroeconomic Environment Analysis 10.1.1 Global Macroeconomic Analysis and Outlook 10.1.2 Chinese Macroeconomic Analysis and Outlook 10.2 Effects to Lungs in Vitro Industry

11 Development Trend Analysis of Lungs in Vitro 11.1 Capacity, Production and Revenue Forecast of Lungs in Vitro by Regions, Types and Applications 11.1.1 Global Capacity, Production and Revenue of Lungs in Vitro by Regions 2019-2024 11.1.2 Global and Major Regions Capacity, Production, Revenue and Growth Rate of Lungs in Vitro 2019-2024 11.1.3 Global Capacity, Production and Revenue of Lungs in Vitro by Types 2019-2024 11.2 Consumption Volume and Consumption Value Forecast of Lungs in Vitro by Regions 11.2.1 Global Consumption Volume and Consumption Value of Lungs in Vitro by Regions 2019-2024 11.2.2 Global and Major Regions Consumption Volume, Consumption Value and Growth Rate of Lungs in Vitro 2019-2024 11.3 Supply, Import, Export and Consumption Forecast of Lungs in Vitro 11.3.1 Supply, Consumption and Gap of Lungs in Vitro 2019-2024 11.3.2 Global Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.3 North America Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.4 Europe Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.5 Asia Pacific Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.6 Middle East & Africa Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024 11.3.7 Latin America Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Lungs in Vitro 2019-2024

12 Contact information of Lungs in Vitro 12.1 Upstream Major Raw Materials and Equipment Suppliers Analysis of Lungs in Vitro 12.1.1 Major Raw Materials Suppliers with Contact Information Analysis of Lungs in Vitro 12.1.2 Major Equipment Suppliers with Contact Information Analysis of Lungs in Vitro 12.2 Downstream Major Consumers Analysis of Lungs in Vitro 12.3 Major Suppliers of Lungs in Vitro with Contact Information 12.4 Supply Chain Relationship Analysis of Lungs in Vitro

13 New Project Investment Feasibility Analysis of Lungs in Vitro 13.1 New Project SWOT Analysis of Lungs in Vitro 13.2 New Project Investment Feasibility Analysis of Lungs in Vitro 13.2.1 Project Name 13.2.2 Investment Budget 13.2.3 Project Product Solutions 13.2.4 Project Schedule

14 Conclusion of the Global Lungs in Vitro Industry 2019 Market Research Report

About Us: Market Research Port is one of the best report resellers in the market bringing to you accurate and trustworthy market research reports by reputed publishers. Our trusted publishers have compiled their reports and findings after painstaking research and studies, set up against varied business parameters. Each report is detailed and then vetted for accuracy by industry experts. In each report, you will find deep analysis, risk analysis, market forecasts, emerging trends, different market segments, technological advancement and its impact, and a multitude of economic factors, giving you the most comprehensive market research report. You get many advantages with such comprehensive reports.

Contact Us: Market Research Port, Brighton Street, Providence, Rhode Island 02929, United States Contact No: +1 401 433 7610 Email: [emailprotected] Website: https://marketresearchport.com/

See the original post here:
Lungs in Vitro Market 2020 Opportunities, Growth Analysis, Trends and Forecast by 2024 | ATCC, Lonza, Epithelix - 3rd Watch News

How COVID-19 Pandemic Will Impact Australia & New Zealand Research Antibodies Market Business Opportunity, And Growth 2020-2026 – 3rd Watch News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Australia & New Zealand Research Antibodies market.

Trusted Business Insights presents an updated and Latest Study on Australia & New Zealand Research Antibodies Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Australia & New Zealand Research Antibodies market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Australia & New Zealand Research Antibodies Market Size Report, 2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Australia & New Zealand Research Antibodies Market

The Australia & New Zealand research antibodies market size was valued at USD 98.4 million in 2018 and is anticipated to grow at a CAGR of 8.4% during the forecast period. Rise in the number of initiatives being undertaken by the Australian government to advance the biotechnology sector is expected to fuel the growth in the country. In May 2019, Federal Labor offered businesses an R&D tax offset for collaborating with science-based agencies and universities, such as The Commonwealth Scientific and Industrial Research Organisation (CSIRO), to promote innovation and knowledge in biotechnology sector. In addition, a 10% tax can be added to the calculated tax offset if a business is collaborating with any public institution. This plan would help in increasing R&D investments in Australia to 3% of GDP by 2030 and is expected to act as a key tool for fostering an alliance between research and industry, thereby improving industrial capabilities in Australia. R&D tax incentive in Australia has encouraged biotechnology companies in the region to conduct R&D. For instance, in 2018, Shape Pharmaceuticals, Inc. supported R&D investments in Australian biotechnology industry by conducting clinical trials to study the effect of SHP-141 on patients diagnosed with psoriasis. These tax incentives help companies achieve cost advantage while selecting clinical trial sites for R&D processes.

Rise in R&D investments by the government is also expected to boost the market. In 2018, the Victorian government allocated USD 1.5 million for establishment of an Advanced Biotechnology Manufacturing Platform to enhance production of antibodies, vaccines, stem cells, and growth factors, among others, for testing in human clinical trials. This facility would enable various Australian biotechnology companies to conduct R&D in the state, thereby generating jobs and propelling growth of various companies currently conducting clinical trials in Victoria. The government is also promoting development of the biotechnology sector through Future Industries Fund. Growth in stem cell and neurobiology-based research is expected to boost the market over the forecast period. The Center of Research Excellence in Neuromuscular Disorders Australia is a wide collaboration of neuromuscular experts, who use advanced technologies and approaches in science & medicine to improve diagnosis. In addition, it aims to transform treatment to effective therapy of neurological diseases from compassionate management. The Australian Neuromuscular Network was formed in the year 2010 by the Center of Research Excellence in Neuromuscular Disorders along with other neuromuscular specialists, scientists, and professionals across New Zealand and Australia. Rise in the prevalence of neurological disorders is expected to boost the market. According to the Neurological Foundation of New Zealand, by 2051, about one-third of the population in New Zealand will be 65 years and above. The prevalence of dementia is therefore expected to increase, leading to a rise in R&D pertaining to treatment for various neurological disorders. However, stringent government regulations that can limit research activities are expected to restrain market growth.

Product Insights of Australia & New Zealand Research Antibodies Market

On basis of product, Australia & New Zealand research antibodies market is segmented into primary and secondary antibodies. Primary antibodies held the largest share and is anticipated to witness the highest CAGR owing to rise in adoption of reagents developed using antibodies, due to the various benefits associated with them such as greater specificity, easy availability, and suitability in various research applications. Similarly, primary antibodies are anticipated to grow at a faster rate during the forecast period due to varied applications in research. In addition, rise in prevalence of chronic diseases, such as diabetes, cancer, and Alzheimers disease, is leading to an increase in adoption of primary antibodies. Increasing R&D in the country is further anticipated to boost the adoption of secondary antibodies as well. Thus, rising adoption of these antibodies in research for development of alternative therapies is anticipated to create significant demand for these products over the forecast period. End-use Insights Pharmaceutical & biotechnology companies held the largest share of the end-use segment in 2018, which can be attributed to increase in adoption of antibodies in drug development and research organizations. Contract research organizations are anticipated to grow at a lucrative CAGR during the forecast period owing to cost-effectiveness.

The academic & research institutes segment is expected to witness constant growth owing to the presence of various academic research groups that are involved in the study of complex biological systems using advanced reagents. Benefits such as greater understanding of biological processes and complex systems are anticipated to create growth opportunities in the segment. Contract research organizations are anticipated to grow at a lucrative CAGR during the forecast period. Majority of the companies prefer CROs owing to the various advantages associated with contract services. These benefits include cost advantage, increased efficiency of services, and enhanced productivity, which help a company focus on its core expertise.

Type Insights of Australia & New Zealand Research Antibodies Market

On the basis of antibody type, the market is segmented into monoclonal and polyclonal antibodies. Monoclonal antibodies held the largest market share due to increase in research on genomics and personalized medicine, which has led to increase in the use of these antibodies. As monoclonal antibodies are relatively cost-effective, they are anticipated to grow at a higher rate than polyclonal antibodies. Polyclonal antibodies have several advantages over monoclonal in various diagnostic settings. Polyclonal antibodies are often the most preferred option in routine laboratory tests such as Enzyme-Linked Immunosorbent Assay (ELISA), microarray assays, western blotting, flow cytometry, and immunohistochemistry. Their production does not require skilled professionals, and large batches can be produced as per client requirements. These antibodies can recognize multiple antigens on one epitope and can therefore be utilized in the study of various diseases ranging from cancer to metabolic Polyclonal antibodies are relatively inexpensive in comparison with monoclonal antibodies, which may fuel their demand in low-budget and non-funded research projects. However, polyclonal antibodies can differ from batch to batch depending upon manufacturing and quality control process. These antibodies can recognize multiple epitopes, thus increasing the probability of nonspecific antigen binding.

Technology Insights of Australia & New Zealand Research Antibodies Market

On the basis of technology, the Australia & New Zealand research antibodies market is segmented into western blotting, immunoprecipitation, immunochemistry, ELISA, immunofluorescence, flow cytometry, and other technologies. Western blotting held the largest share of the technology segment in 2018 owing to rising demand for rapid diagnostic methods. On the other hand, technical upgradation is anticipated to create growth prospects for technologies in pipeline. ELISA is anticipated to witness the highest CAGR during the forecast period owing to conventional use of polyclonal antibodies in sandwich ELISA. ELISA is an analytical test that essentially uses antibodies to identify substances in samples. These tests are most often used to accurately diagnose diseases, such as AIDS, Lyme disease, syphilis, pernicious anemia, Rocky Mountain spotted fever, squamous cell carcinoma, chickenpox, shingles, and other bacterial & viral infections. Western blotting held the largest share in 2018 owing to rise in prevalence of diseases with limited number of treatment options. Western blotting offers high accuracy and sensitivity and is considered a gold standard for testing. In addition, increase in government initiatives to fund research activities is one of the factors contributing to the highest market share held by this segment, as it is conventionally used in research laboratories. Source Insights The mouse segment held the largest share in 2018 as mice are convenient to use during production of antibodies for research purposes and have wide range of applications. Others segment is expected to grow exponentially, as it has a wide range of applications. The use of murine monoclonal antibodies is increasing in various end-use settings, which is expected to positively impact market growth. Mice have been predominantly used in production of antibodies. The structural similarities in mice and human antibodies is a prime factor responsible for high adoption. Cost-effectiveness and the ability to multiply quickly are among the factors fueling growth of this segment. Moreover, mouse-derived monoclonal and polyclonal antibodies are relatively easier to produce and possess greater specificity. Technological advancements in the development processes of these products, such as hybridoma technology that aids in production of monoclonal antibodies in specialized cells, are further augmenting demand for mouse antibodies. Rabbits are also extensively used for production of antibodies, owing to various advantages such as higher affinity and specificity in comparison with antisera obtained from other animal hosts. Higher specificity of these products makes them ideal for use in detection of small molecules, such as pollutants; toxins; hormones; drugs; nonprotein targets, such as carbohydrates & lipids; and post-translational alterations such as phosphorylation.

Application Insights of Australia & New Zealand Research Antibodies Market

Oncology held the largest share of the application segment in 2018. The largest share can be attributed to growing prevalence of cancer, which leads to an increase in the need for R&D pertaining to advanced therapeutics. On the other hand, stem cell is anticipated to witness lucrative CAGR during the forecast period owing to significant increase in stem cells research. Rising prevalence of infectious diseases, growing geriatric population, decreasing immunity levels, and rising awareness among people about communicable diseases are some of the high impact-rendering drivers of the market. Growing incidence of autoimmune diseases coupled with limited presence of advanced therapeutics is predominantly driving segment growth. Significant advancements in immunology research have boosted adoption of research antibodies in the recent years. Oncology accounted for the largest share of research antibodies in 2018.The segment is also anticipated to grow at a considerable CAGR owing to increasing incidence of cancer. According to WHO, the number of new cancer cases is anticipated to increase by approximately 70.0% in the next two decades. Monoclonal antibodies are also used for diagnosis of lymphoid & myeloid malignancies, tissue typing, and immunological intervention using passive antibody. Owing to the steady increase in the demand for transplantable tissues and low-quality donor cells, stem cell research segment is expected to grow. Moreover, increasing adoption of cell isolation and culture, which involves use of research antibodies, is further anticipated to broaden segment growth prospects.

Market Share Insights of Australia & New Zealand Research Antibodies Market

Some major players in this market are PerkinElmer, Inc.; F.Hoffmann La Roche Ltd.; Thermo Fisher Scientific; Merck Millipore; Bio-Rad Laboratories; Abcam PLC; BD; Lonza Group; Cell Signaling Technology, Inc.; and Agilent Technologies. Increase in the number of products launched by market players is expected to fuel market growth. For instance, in April 2019, Bio-Rad launched a range of isotype-specific secondary antibodies-IgG1, IgG2a, and IgG2b. These products are used to offer specificity when used in ELISA, imaging, western blotting, and flow cytometry, among others, as well as for improved signaling. Mergers & acquisitions and collaborations are some of the other strategic initiatives undertaken by leading players to gain market share, for instance, Abcam Plc acquired Calico Biolabs. This initiative helped the company expand its product portfolio through the addition of high-quality recombinant rabbit monoclonal antibodies for immunohistochemistry. As per the agreement, Abcam was to also expand its custom rabbit monoclonal antibody production. These factors are further anticipated to aid growth during the forecast period.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Australia & New Zealand Research Antibodies Market Research Report This report forecasts revenue growth at country level and provides an analysis on the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the Australia & New Zealand research antibodies market report on the basis of product, type, technology, source application, end use, and country:

Product Outlook (Revenue, USD Million, 2019 2030)

Primary

Secondary

Type Outlook (Revenue, USD Million, 2019 2030)

Monoclonal Antibodies

Polyclonal Antibodies

Technology Outlook (Revenue, USD Million, 2019 2030)

Immunohistochemistry

Immunofluorescence

Western Blotting

Flow Cytometry

Immunoprecipitation

ELISA

Others

Source Outlook (Revenue, USD Million, 2019 2030)

Mouse

Rabbit

Goat

Others

Application Outlook (Revenue, USD Million, 2019 2030)

Infectious Diseases

Immunology

Oncology

Stem Cells

Neurobiology

Others

End-use Outlook (Revenue, USD Million, 2019 2030)

Academic & Research Institutes

Contract Research Organizations

Pharmaceutical & Biotechnology Companies

Quick Read Table of Contents of this Report @ Australia & New Zealand Research Antibodies Market Size Report, 2026 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

See the article here:
How COVID-19 Pandemic Will Impact Australia & New Zealand Research Antibodies Market Business Opportunity, And Growth 2020-2026 - 3rd Watch News

Stem Cell Therapy Market to 2027 Global Analysis and Forecast by Type, Treatment, End User – Apsters News

Stem Cell Therapy Market Insights 2020

Increasing Awareness Related to the Stem Cells Therapy in Effective Disease Management

Stem cell research has been widely investigated globally to enhance human health in a medical setting. For this, creating public awareness about stem cell research is vital for realizing this potential. The stem cells main role is to replace dying cells and reconstruct damaged tissues. Based on the extensive stem cell research results, many scientists have claimed that the cells could probably generate cures and treatment for various diseases, including cancers, cardiovascular disease, and others. Newly developed stem cell therapies having the capability to replace disease, causing cells. Hence, patients now started relying on stem cell therapy that has long term positive outcomes. There is an increasing number of potential treatments that are undergoing in clinical trials phase. The FDA has approved very few stem cell therapies. For instance, in 2019, Fedratinib, approved by the FDA for the first-line treatment for fibrosis. Bone marrow transplantation is widely used stem cell based therapy. Blood forming stem cells were the first to be used in the clinic. This stem cell therapy has benefited thousands of patients who have leukemia.

Download sample PDF copy at:https://www.theinsightpartners.com/sample/TIPHE100000991/

Strategic Insights

Product launches and FDA approvals strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.

The market players operating in the stem cell therapy market adopt the strategy of collaborations to enlarge customer base across the world, which also permits the players to maintain their brand name globally.

Company Profiles

The stem cell therapy market is expected to grow, owing to factors such Increasing awareness related to the stem cells therapy in effective disease management, growing demand for regenerative medicines, and growing cancer prevalence across the globe are likely to have a positive impact on the growth of the market in coming years.

Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

Continued here:
Stem Cell Therapy Market to 2027 Global Analysis and Forecast by Type, Treatment, End User - Apsters News